Literature DB >> 17652722

Role of macrophage migration inhibitory factor in corneal neovascularization.

Tomohiko Usui1, Satoru Yamagami, Shuichi Kishimoto, Yokoo Seiich, Toshinori Nakayama, Shiro Amano.   

Abstract

PURPOSE: To determine the role of macrophage migration inhibitory factor (MIF) in inflammatory corneal neovascularization.
METHODS: Corneal neovascularization was induced by suturing 10-0 nylon 1 mm away from limbal vessel or limbal scraping after 0.15 M NaOH application in BALB/c mice. MIF expression was evaluated by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), Western blot analysis, and immunohistochemistry. To investigate the function of MIF in inflammatory corneal neovascularization, the neovascularized area and number of infiltrating F4/80-positive cells (monocytes/macrophages) were compared between wild-type mice and homozygous MIF-deficient mice.
RESULTS: MIF mRNA and protein markedly increased in the neovascularized corneas compared with normal corneas by RT-PCR and Western blot analysis, respectively. MIF expression was upregulated immunohistochemically, not only in the corneal epithelium but also in the stromal infiltrating cells of neovascularized corneas. Neovascularized area in corneas of MIF(-/-) mice was significantly small compared with that in wild-type mice on day 7 after corneal suture and on day 14 after limbal scrape, and MIF(-/-) cornea had approximately 30% less neovascularized area than did wild-type cornea in both models. Neovascularized corneas in MIF-deficient mice had significantly fewer monocytes/macrophages than those in wild-type control mice.
CONCLUSIONS: These findings indicate that MIF, abundantly expressed in neovascularized corneas, has an angiogenic role in inflammatory corneal neovascularization and may be a therapeutic target for suppression of corneal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652722     DOI: 10.1167/iovs.06-0695

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Short- and long-term corneal vascular effects of tafluprost eye drops.

Authors:  Deniz Hos; Konrad R Koch; Felix Bock; Rafael S Grajewski; Thomas S Dietlein; Claus Cursiefen; Ludwig M Heindl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-28       Impact factor: 3.117

Review 2.  Corneal transparency: genesis, maintenance and dysfunction.

Authors:  Yureeda Qazi; Gilbert Wong; Bryan Monson; Jack Stringham; Balamurali K Ambati
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

3.  The role of macrophage migration inhibitory factor in ocular surface disease pathogenesis after chemical burn in the murine eye.

Authors:  Sei Yeul Oh; Jong-Sun Choi; Eo-Jin Kim; Roy S Chuck; Choul Yong Park
Journal:  Mol Vis       Date:  2010-11-17       Impact factor: 2.367

4.  Celastrol nanoparticles inhibit corneal neovascularization induced by suturing in rats.

Authors:  Zhanrong Li; Lin Yao; Jingguo Li; Wenxin Zhang; Xianghua Wu; Yi Liu; Miaoli Lin; Wenru Su; Yongping Li; Dan Liang
Journal:  Int J Nanomedicine       Date:  2012-03-01

5.  Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model.

Authors:  Lei Zhu; Jikui Shen; Cheng Zhang; Choul Yong Park; Sahar Kohanim; Margaret Yew; John S Parker; Roy S Chuck
Journal:  Mol Vis       Date:  2009-01-30       Impact factor: 2.367

6.  Macrophage migration inhibitory factor promotes cardiac stem cell proliferation and endothelial differentiation through the activation of the PI3K/Akt/mTOR and AMPK pathways.

Authors:  Jinjin Cui; Fengyun Zhang; Yongshun Wang; Jingjin Liu; Xing Ming; Jingbo Hou; Bo Lv; Shaohong Fang; Bo Yu
Journal:  Int J Mol Med       Date:  2016-03-29       Impact factor: 4.101

7.  The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ajmal Ahmad; Mohammad Mairaj Siddiquei; Alexandra De Zutter; Eef Allegaert; Priscilla W Gikandi; Gert De Hertogh; Jo Van Damme; Ghislain Opdenakker; Sofie Struyf
Journal:  Front Immunol       Date:  2019-12-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.